FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907777653> ?p ?o ?g. }

• W2907777653 endingPage "100" @default.
• W2907777653 startingPage "89" @default.
• W2907777653 abstract "Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States. Few studies have investigated prescribing patterns among rheumatologists who have initiated secukinumab for the treatment of patients with PsA in real-world settings. This US medical chart review describes clinical and treatment characteristics of patients with psoriatic arthritis (PsA) who were prescribed secukinumab and rheumatologist-reported reasons for prescribing secukinumab in clinical practice.This US medical chart review included patients with physician-diagnosed PsA aged ≥ 18 years initiating secukinumab after January 15, 2016. Eligible rheumatologists used online forms to collect patient demographics, disease characteristics, comorbidity profiles, and treatment histories before or on the date of the first secukinumab prescription recorded in the medical chart. Information on reasons for secukinumab prescription and dosing was also collected.Medical charts from 153 patients with PsA who initiated secukinumab were reviewed by 46 rheumatologists between July 7, 2017, and August 11, 2017. Overall, 53.6% of patients were male, mean (standard deviation) age was 47.3 (11.5) years, and 24.8% were biologic naive. The most common reasons for secukinumab prescription among biologic-naive and biologic-experienced patients, respectively, were efficacy/effectiveness of secukinumab (84.2%) and failure of other prior biologics (80.9%). Nearly all patients (94.1%) received a loading regimen, including 150 mg every week (32.7%) and 300 mg every week (61.4%). Overall, 145 patients (94.8%) received ≥ 1 maintenance dose, of whom 49.7% received 150 mg every 4 weeks and 50.3% received 300 mg every 4 weeks.At the time of the chart review, most patients with PsA who initiated secukinumab were biologic experienced, although one-quarter received secukinumab as first-line biologic therapy. Efficacy/effectiveness of secukinumab and failure of other biologics were the most common reasons for initiating secukinumab.Novartis Pharmaceuticals Corporation, East Hanover, NJ. Plain language summary available for this article." @default.
• W2907777653 created "2019-01-11" @default.
• W2907777653 creator A5012501013 @default.
• W2907777653 creator A5024802357 @default.
• W2907777653 creator A5052149671 @default.
• W2907777653 creator A5060607239 @default.
• W2907777653 creator A5077592945 @default.
• W2907777653 creator A5085492465 @default.
• W2907777653 date "2019-01-05" @default.
• W2907777653 modified "2023-10-18" @default.
• W2907777653 title "Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review" @default.
• W2907777653 cites W1915713161 @default.
• W2907777653 cites W1935617463 @default.
• W2907777653 cites W1973040111 @default.
• W2907777653 cites W2023149067 @default.
• W2907777653 cites W2034350610 @default.
• W2907777653 cites W2078157933 @default.
• W2907777653 cites W2102347458 @default.
• W2907777653 cites W2103524303 @default.
• W2907777653 cites W2108984264 @default.
• W2907777653 cites W2113717019 @default.
• W2907777653 cites W2120407721 @default.
• W2907777653 cites W2128325185 @default.
• W2907777653 cites W2137101132 @default.
• W2907777653 cites W2142905097 @default.
• W2907777653 cites W2154464235 @default.
• W2907777653 cites W2166077573 @default.
• W2907777653 cites W2166494000 @default.
• W2907777653 cites W2194197257 @default.
• W2907777653 cites W2218980995 @default.
• W2907777653 cites W2223868808 @default.
• W2907777653 cites W2266045195 @default.
• W2907777653 cites W2386234576 @default.
• W2907777653 cites W2471133371 @default.
• W2907777653 cites W2512436288 @default.
• W2907777653 cites W2529992459 @default.
• W2907777653 cites W2586118822 @default.
• W2907777653 cites W2599076725 @default.
• W2907777653 cites W2611521096 @default.
• W2907777653 cites W2620369605 @default.
• W2907777653 cites W2766717228 @default.
• W2907777653 cites W2766846920 @default.
• W2907777653 cites W2789710874 @default.
• W2907777653 cites W4292229870 @default.
• W2907777653 doi "https://doi.org/10.1007/s40744-018-0137-z" @default.
• W2907777653 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6393268" @default.
• W2907777653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30612321" @default.
• W2907777653 hasPublicationYear "2019" @default.
• W2907777653 type Work @default.
• W2907777653 sameAs 2907777653 @default.
• W2907777653 citedByCount "7" @default.
• W2907777653 countsByYear W29077776532020 @default.
• W2907777653 countsByYear W29077776532021 @default.
• W2907777653 countsByYear W29077776532022 @default.
• W2907777653 countsByYear W29077776532023 @default.
• W2907777653 crossrefType "journal-article" @default.
• W2907777653 hasAuthorship W2907777653A5012501013 @default.
• W2907777653 hasAuthorship W2907777653A5024802357 @default.
• W2907777653 hasAuthorship W2907777653A5052149671 @default.
• W2907777653 hasAuthorship W2907777653A5060607239 @default.
• W2907777653 hasAuthorship W2907777653A5077592945 @default.
• W2907777653 hasAuthorship W2907777653A5085492465 @default.
• W2907777653 hasBestOaLocation W29077776531 @default.
• W2907777653 hasConcept C126322002 @default.
• W2907777653 hasConcept C2426938 @default.
• W2907777653 hasConcept C2776260265 @default.
• W2907777653 hasConcept C2777288759 @default.
• W2907777653 hasConcept C2777575956 @default.
• W2907777653 hasConcept C2778715236 @default.
• W2907777653 hasConcept C2779786854 @default.
• W2907777653 hasConcept C71924100 @default.
• W2907777653 hasConcept C98274493 @default.
• W2907777653 hasConceptScore W2907777653C126322002 @default.
• W2907777653 hasConceptScore W2907777653C2426938 @default.
• W2907777653 hasConceptScore W2907777653C2776260265 @default.
• W2907777653 hasConceptScore W2907777653C2777288759 @default.
• W2907777653 hasConceptScore W2907777653C2777575956 @default.
• W2907777653 hasConceptScore W2907777653C2778715236 @default.
• W2907777653 hasConceptScore W2907777653C2779786854 @default.
• W2907777653 hasConceptScore W2907777653C71924100 @default.
• W2907777653 hasConceptScore W2907777653C98274493 @default.
• W2907777653 hasIssue "1" @default.
• W2907777653 hasLocation W29077776531 @default.
• W2907777653 hasLocation W29077776532 @default.
• W2907777653 hasLocation W29077776533 @default.
• W2907777653 hasLocation W29077776534 @default.
• W2907777653 hasLocation W29077776535 @default.
• W2907777653 hasOpenAccess W2907777653 @default.
• W2907777653 hasPrimaryLocation W29077776531 @default.
• W2907777653 hasRelatedWork W2909991553 @default.
• W2907777653 hasRelatedWork W2946910872 @default.
• W2907777653 hasRelatedWork W3011669636 @default.
• W2907777653 hasRelatedWork W3034321784 @default.
• W2907777653 hasRelatedWork W3109586120 @default.
• W2907777653 hasRelatedWork W3118690665 @default.
• W2907777653 hasRelatedWork W3165270464 @default.
• W2907777653 hasRelatedWork W4246832057 @default.
• W2907777653 hasRelatedWork W4293229883 @default.

• next